



EPICS

CONGRESS COVERAGE: ESMO 2020 HIGHLIGHTS – GU MALIGNANCIES

September 2020

- > On September 23, 2020, following the European Society for Medical Oncology (ESMO) Virtual Congress, Aptitude Health brought together a group of scientists and clinical investigators with expertise in genitourinary (GU) malignancies to attend the Emerging Paradigms in Care Series (EPICS) Congress Coverage meeting
- > The goal of the expert panel was to critique and debate new evidence in GU cancers and gain strategic insight into the most impactful abstracts from the ESMO meeting with respect to shaping current research directions and/or changing the scope of practical clinical care

FACULTY EXPERTS

Chair
Daniel Petrylak, MD



Karim Fizazi, MD, PhD



Leonard Gomella, MD



David Nanus, MD



Oliver Sartor, MD



Cora Sternberg, MD



Scott Tagawa, MD

Time EST	Topic	Speaker/Moderator
8.00 AM – 8.05 AM	Welcome and Introductions	Daniel Petrylak, MD
8.05 AM – 8.20 AM	Prostate Cancer – Cytotoxic, Hormonal, and Immune-Based Therapies	Oliver Sartor, MD
8.20 AM – 8.35 AM	Discussion: Prostate Cancer – Cytotoxic, Hormonal, and Immune-Based Therapies	All Moderator: Daniel Petrylak, MD
8.35 AM – 8.40 AM	Summary and Key Takeaways – Prostate Part 1	Oliver Sartor, MD
8.40 AM – 8.55 AM	Targeting Intracellular Signaling and DNA Damage Repair Pathways in Metastatic Prostate Cancer	Karim Fizazi, MD, PhD
8.55 AM – 9.10 AM	Discussion: Targeting Intracellular Signaling and DNA Damage Repair Pathways in Metastatic Prostate Cancer	All Moderator: Daniel Petrylak, MD
9.10 AM – 9.15 AM	Summary and Key Takeaways – Prostate Part 2	Karim Fizazi, MD, PhD
9.15 AM – 9.25 AM	Break	
9.25 AM – 9.40 AM	Renal Cell Carcinoma	David Nanus, MD
9.40 AM – 10.05 AM	Discussion: Renal Cell Carcinoma	All Moderator: Daniel Petrylak, MD
10.05 AM – 10.10 AM	Summary and Key Takeaways – RCC	David Nanus, MD
10.10 AM – 10.20 AM	Bladder Cancer – Immunotherapies	Cora Sternberg, MD
10.20 AM – 10.35 AM	Discussion: Bladder Cancer – Immunotherapies	All Moderator: Daniel Petrylak, MD
10.35 AM – 10.40 AM	Bladder Cancer – ADCs	Scott Tagawa, MD
10.40 AM – 10.50 AM	Discussion: Bladder Cancer – ADCs	All Moderator: Daniel Petrylak, MD
10.50 AM – 10.55 AM	Summary and Key Takeaways – Bladder Cancer	Cora Sternberg, MD
10.55 AM – 11.00 AM	Summary and Closing Remarks	Daniel Petrylak, MD

 A large, stylized logo consisting of several thick, dark blue curved lines that form a circular, sunburst-like pattern. The lines are arranged in a way that they appear to be part of a larger, repeating geometric design.

EPICS

Prostate Cancer – Cytotoxic, Hormonal, and Immune-Based Therapies

OLIVER SARTOR, MD

PROSTATE CANCER – CYTOTOXIC, HORMONAL, AND IMMUNE-BASED THERAPIES: ABSTRACTS (1/5)

- > Abstract 6110 – Abiraterone acetate plus prednisolone for hormone-naïve prostate cancer (PCa):

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

PROSTATE CANCER – CYTOTOXIC, HORMONAL, AND IMMUNE-BASED THERAPIES: ABSTRACTS (2/5)

> Abstract 6090 – Results from a phase 1 study of AMG 160, a half-life extended (HLE), PSMA-

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

PROSTATE CANCER – CYTOTOXIC, HORMONAL, AND IMMUNE-BASED THERAPIES: ABSTRACTS (3/5)

- > Abstract 615MO – Phase 1b/2 study of VERU-111, novel, oral tubulin inhibitor, in men with

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

PROSTATE CANCER – CYTOTOXIC, HORMONAL, AND IMMUNE-BASED THERAPIES: ABSTRACTS (4/5)

- > Abstract 616MO – Efficacy of BN-brachyury (BNVax) + Bintrafusp alfa (BA) + N-803 in Castration-

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

PROSTATE CANCER – CYTOTOXIC, HORMONAL, AND IMMUNE-BASED THERAPIES: ABSTRACTS (5/5)

- > Abstract 617MO – Repurposing Metformin as anticancer drug: Preliminary results of randomized

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

PROSTATE CANCER – CYTOTOXIC, HORMONAL, AND IMMUNE-BASED THERAPIES: DISCUSSION (1/3)

- > The long-term OS data from STAMPEDE in both the higher- and lower-risk populations of patients with

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

PROSTATE CANCER – CYTOTOXIC, HORMONAL, AND IMMUNE-BASED THERAPIES: DISCUSSION (2/3)

- > There are now a number of options that have been shown to improve OS in patients with CSPC

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

PROSTATE CANCER – CYTOTOXIC, HORMONAL, AND IMMUNE-BASED THERAPIES: DISCUSSION (3/3)

> Novel agents (contd)

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

 A large, stylized logo consisting of several thick, dark blue curved lines that form a circular, sunburst-like pattern. The lines are arranged in a way that they appear to be radiating from a central point, creating a sense of movement and energy.

EPICS

**Targeting Intracellular
Signaling and DNA Damage
Repair Pathways in
Metastatic Prostate Cancer**

KARIM FIZAZI, MD, PHD

TARGETING INTRACELLULAR SIGNALING AND DNA DAMAGE REPAIR PATHWAYS IN METASTATIC PROSTATE CANCER: ABSTRACTS (1/3)

EPICS

- > Abstract 6100 – Final overall survival (OS) analysis of PROfound: olaparib vs physician’s choice of

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

TARGETING INTRACELLULAR SIGNALING AND DNA DAMAGE REPAIR PATHWAYS IN METASTATIC PROSTATE CANCER: ABSTRACTS (2/3)

EPICS

- > Abstract 614MO – Cabazitaxel (CBZ) activity in men with metastatic castration resistant prostate

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

TARGETING INTRACELLULAR SIGNALING AND DNA DAMAGE REPAIR PATHWAYS IN METASTATIC PROSTATE CANCER: ABSTRACTS (3/3)

EPICS

- > Abstract LBA4 – IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

TARGETING INTRACELLULAR SIGNALING AND DNA DAMAGE REPAIR PATHWAYS IN METASTATIC PROSTATE CANCER: DISCUSSION (1/3)

EPICS

- > The OS benefit seen in the PROfound trial with olaparib in HRR-altered mCRPC is viewed as very

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

TARGETING INTRACELLULAR SIGNALING AND DNA DAMAGE REPAIR PATHWAYS IN METASTATIC PROSTATE CANCER: DISCUSSION (2/3)

- > The data with ipatasertib + abiraterone in the IPATential150 trial are considered positive, but some

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

TARGETING INTRACELLULAR SIGNALING AND DNA DAMAGE REPAIR PATHWAYS IN METASTATIC PROSTATE CANCER: DISCUSSION (3/3)

EPICS

- > Experts found reassuring the retrospective data suggesting that cabazitaxel is effective regardless

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT



EPICS

Renal Cell Carcinoma

DAVID NANUS, MD

- > Abstract 696O – Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

- > Abstract 7020 – Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

- > Abstract LBA25 – Results from the phase 2 BIOMarker driven trial with Nivolumab (N) and

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

- > Abstract 7000 – Kidney ccRCC Immune Classification (KIC) enhances the predictive value of T

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

- > Abstract 701O – Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

- > Abstract LBA26 – Phase 2 Study of the Oral HIF-2 α Inhibitor MK-6482 for Von Hippel-Lindau (VHL)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

RENAL CELL CARCINOMA: DISCUSSION (1/3)

- > The combination of cabozantinib + nivolumab is likely to gain regulatory approval as a first-line therapy for mRCC on the basis of results from the CheckMate 9ER trial

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

- > Atezolizumab in combination with cabozantinib is also perceived to have strong antitumor activity in

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

- > Molecular biomarkers, including transcriptomics and IHC, are showing promise for identifying patients for IO

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

 A large, dark blue stylized logo consisting of several thick, curved lines that form a circular, sunburst-like shape, positioned on the left side of the slide.

EPICS

Bladder Cancer – Immunotherapies

CORA STERNBERG, MD

- > Abstract 6970 – A phase 3, randomized, open-label study of first-line durvalumab (D) with or

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

- > Abstract LBA23 – Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L)

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

- > Abstract 704MO – Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

- > Abstract 6990 – Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

- > Abstract LBA27 – Phase II multicenter, randomized study to evaluate efficacy and safety of

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

- > Abstract 698O – Patient-reported outcomes (PROs) from IMvigor130: a global, randomised,

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

- > Abstract 705MO – Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

- > Experts were surprised by the negative results of the KEYNOTE-361 trial evaluating

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

- > More effort is needed to identify biomarkers to differentiate patients with platinum-eligible mUC who

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

- > The results of the DANUBE trial, which did not meet either of the co-primary endpoints, are

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

 A large, dark blue, stylized logo consisting of several thick, curved lines that form a circular, sunburst-like pattern. The lines are thick and have a slight taper at the ends, creating a sense of movement and energy.

EPICS

Bladder Cancer – ADCs

SCOTT TAGAWA, MD

BLADDER CANCER – ANTIBODY-DRUG CONJUGATES: ABSTRACTS (1/3)

- > Abstract LBA24 – TROPHY-U-01 Cohort 1 Final Results: A Phase 2 Study of Sacituzumab

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

BLADDER CANCER – ANTIBODY-DRUG CONJUGATES: ABSTRACTS (2/3)

- > Abstract 746P – EV-201: Long-term results of enfortumab vedotin monotherapy for locally

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

BLADDER CANCER – ANTIBODY-DRUG CONJUGATES: ABSTRACTS (3/3)

- > Abstract 771P – Efficacy of enfortumab vedotin in populations of interest among patients with

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

BLADDER CANCER – ANTIBODY-DRUG CONJUGATES: DISCUSSION (1/2)

- > Data with EV and sacituzumab govitecan suggest remarkable consistency across early phase and

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

BLADDER CANCER – ANTIBODY-DRUG CONJUGATES: DISCUSSION (2/2)

- > Experts found reassuring the retrospective data regarding patients treated with EV in a real-world

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

 A large, dark blue, stylized logo consisting of several thick, curved lines that form a circular, sunburst-like shape, positioned on the left side of the slide.

EPICS

Key Highlights and Strategic Takeaways

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT